echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > The Synthetic Routes of (S)-trans-2-Amino-4-(2-aminoethoxy)-3-butenoic acid hydrochloride

    The Synthetic Routes of (S)-trans-2-Amino-4-(2-aminoethoxy)-3-butenoic acid hydrochloride

    • Last Update: 2023-04-25
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    (S)-trans-2-Amino-4-(2-aminoethoxy)-3-butenoic acid hydrochloride, also known as Linezolid, is an antibiotic agent used to treat various bacterial infections.
    The synthesis of Linezolid involves several steps, and there are several synthetic routes that can be used to synthesize this compound.
    In this article, we will discuss some of the most common synthetic routes for Linezolid and their significance in the chemical industry.


    One of the most common synthetic routes for Linezolid involves the reduction of N-phenylanthranilic acid to form N-phenyl-2-aminothiazolidine-4-carboxylic acid.
    This step is followed by the nucleophilic substitution of the carboxylic acid with 2-amino-4-(2-aminoethoxy)-3-butenoic acid to form the desired compound.
    This route is a multi-step process that requires the use of several chemical reagents and solvents, but it is widely used due to its high yield and cost-effectiveness.


    Another synthetic route for Linezolid involves the use of a "one-pot" reaction, where the N-phenylanthranilic acid is treated with 2-amino-4-(2-aminoethoxy)-3-butenoic acid and several other reagents in the presence of a base.
    This reaction results in the formation of the desired compound, as well as the concurrent formation of the byproduct N-phenyl-2-aminothiazolidine-4-carboxylic acid.
    This route is more efficient than the multi-step process described above, as it combines several steps into a single reaction, making it easier to scale up and more cost-effective.


    There are also several other synthetic routes for Linezolid, including those that involve the use of enzymes or biotechnology.
    For example, one route involves the use of a whole-cell biocatalyst that employs a bacterial strain to convert N-phenylanthranilic acid to Linezolid.
    This route is more environmentally friendly, as it does not require the use of toxic chemical reagents, but it is currently less cost-effective than the chemical synthesis routes.


    In summary, there are several synthetic routes for Linezolid, each with its own advantages and disadvantages.
    The most commonly used routes involve the reduction of N-phenylanthranilic acid to form N-phenyl-2-aminothiazolidine-4-carboxylic acid, followed by nucleophilic substitution with 2-amino-4-(2-aminoethoxy)-3-butenoic acid.
    Other routes involve the use of one-pot reactions or enzymes, and each route has its own advantages and limitations.
    Ultimately, the choice of synthetic route for Linezolid will depend on the specific needs of the chemical industry and the desired cost and efficiency trade-offs.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.